Sen. Grassley urges FDA to implement recommendations of Inspector General for human subjects in clinical trials
WASHINGTON — Sen. Chuck Grassley is calling on the Food and Drug Administration to implement recommendations stemming from an independent review of the agency’s oversight of clinical trials involving human subjects.
“We’re all in debt to the individuals who volunteer for the clinical trials that advance medicine and lead to lifesaving cures. The Food and Drug Administration needs to make sure these human subjects are treated properly and fully informed,” Grassley said.
Grassley made his appeal in a letter to the FDA Commissioner. The text is below. The report of the Inspector General for the Department of Health and Human Services containing the recommendations is posted at http://finance.senate.gov, along with this news release.
Next Article Previous Article
- Wyden Statement on Trump Trial Balloon on Executive Actions on Unemployment Benefits, Payroll Tax Cut
- Wyden, Feinstein Lead Senate Democrats to Protect Health Care Freedoms in Court
- Wyden, Brown, Cortez Masto, MomsRising, Workers Call For $600 Weekly Boost to Unemployment Benefits to Be Reinstated
- Wyden Statement on Treasury Department's Carried Interest Regulations
- Wyden Solicits Stories from Frontline Health Care Workers Struggling to Get PPE